home / stock / cytx / cytx news


CYTX News and Press, Cytori Therapeutics Inc.

Stock Information

Company Name: Cytori Therapeutics Inc.
Stock Symbol: CYTX
Market: NASDAQ
Website: cytori.com

Menu

CYTX CYTX Quote CYTX Short CYTX News CYTX Articles CYTX Message Board
Get CYTX Alerts

News, Short Squeeze, Breakout and More Instantly...

CYTX - Cytori to become Plus Therapeutics

Citing the need for a new identity to coincide with its new direction, Cytori Therapeutics (NASDAQ: CYTX ) will change its name to Plus Therapeutics (PSTV). The change will take effect in several weeks. More news on: Cytori Therapeutics, Inc., Healthcare stocks news, Read more ...

CYTX - Cytori Will Become Plus Therapeutics, Inc.

AUSTIN, Texas, July 16, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq: CYTX) (the “company”) announced yesterday a new direction and identity. Since the beginning of 2019, the company has successfully evaluated and transformed its pipeline to place a stronger e...

CYTX - Key events next week - healthcare

Noteworthy events during the week of July 14 - 20 for healthcare investors. More news on: ProMIS Neurosciences, Inc., Cortexyme, Inc., Cytori Therapeutics, Inc., Healthcare stocks news, , Read more ...

CYTX - Cytori to Present Corporate Update & New Strategic Direction

SAN DIEGO, July 11, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) “the Company” will provide a live webcast to discuss its new company direction following two recent asset sales and highlight key anticipated milestones on July 15, 2019 at 4:30 PM Eastern Ti...

CYTX - Cytori Reports Summary of FDA Feedback Regarding its ATI-1123 Product

AUSTIN, Texas, July 01, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) today provided an update on the development of its proprietary drug, ATI-1123, based on recently obtained feedback from the United States Food and Drug Administration (FDA). ATI-1123 is a substantially...

CYTX - Cytori Reports Summary of FDA Feedback Regarding its ATI-1123 Product

AUSTIN, Texas, July 01, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) today provided an update on the development of its proprietary drug, ATI-1123, based on recently obtained feedback from the United States Food and Drug Administration (FDA). ATI-1123 is a substantially...

CYTX - Cytori Announces New Annual Stockholders Meeting Date for July 11

SAN DIEGO, June 27, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq: CYTX) today announced that it reconvened its annual meeting of stockholders on Thursday, June 27, 2019 and adjourned the meeting until Thursday, July 11, 2019, at 9:00 a.m., Central Time. The annual meeting was ...

CYTX - Cytori Announces New Annual Stockholders Meeting Date for June 27

SAN DIEGO, June 19, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq: CYTX) today announced that it reconvened its annual meeting of stockholders on Tuesday, June 18, 2019 and adjourned the meeting until Thursday, June 27, 2019, at 9:00 a.m., Central Time. The annual meeting was a...

CYTX - The Stem Cell Triple Play: 3 Companies WIth Great Value Drivers

Regenerative medicine has made steady progress over the last few years, but, with few exceptions, little of that progress has been reflected in appreciating stock prices. From an investor’s mindset, there should be a balanced perspective that weighs the promise of explosive revenue grow...

CYTX - Cytori to Present New Strategic Direction

SAN DIEGO, June 13, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) “the Company” will provide a live webcast to discuss its continued transformation efforts following two recent asset sales and highlight key anticipated milestones on June 19, 2019 at 4:15 PM...

Next 10